Mar 24, 2020 / 12:30PM GMT
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Novavax NanoFlu achieves all primary endpoints in the Phase III clinical trials conference call. (Operator Instructions)
I would now like to introduce your host for today's conference call, Ms. Erika Trahan, Senior Manager of Investor Relations and Public Relations. You may begin.
Erika S. Trahan - Novavax, Inc. - Senior Manager of Investor & Public Relations
Thank you, operator. Good morning. I'd like to thank everyone who has joined today's call to discuss our Phase III NanoFlu results. A press release announcing our results is currently available on our website at novavax.com, and an audio archive of this conference call will be available on our website later today.
Joining me on today's call are Stan Erck, President and CEO of Novavax; John Trizzino, Chief Business Officer and Chief Financial Officer; and Dr. Gregory Glenn, our President of Research and Development, will be available for the Q&A portion of the call.
Before we begin with prepared remarks,
Novavax, Inc. - Special Call Transcript
Mar 24, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers